Anti-CD47 Antibody Dosing for Solid Tumors Without Priming Dose
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a critical need for anticancer agents with safety, tolerability, and efficacy for patients with advanced or metastatic cancers, as current treatments like magrolimab have safety concerns and there are no established therapeutic alternatives.
Innovation Solution
A method involving the administration of an anti-CD47 antibody, specifically IMC-002, at doses of 5 mg/kg to 30 mg/kg every 2 to 3 weeks, without a priming dose, to treat advanced or metastatic solid cancers, which targets CD47 and inhibits the interaction between CD47 and SIRPα, enhancing macrophage-mediated phagocytosis and suppressing tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If magrolimab is used as an anti-CD47 antibody for cancer treatment, then antitumor activity is enhanced through macrophage-mediated phagocytosis, but serious safety concerns arise including hemagglutination and anemia
Solution Approach 1:
The patent applies local quality by engineering the antibody to have different binding properties at different sites. The anti-CD47 antibody is designed with modified CDR regions that maintain high affinity for CD47 on cancer cells while having reduced affinity for CD59 on red blood cells, thereby achieving selective action on target cells while sparing non-target cells
Solution Approach 2:
The patent changes the molecular parameters of the antibody by modifying the amino acid sequences in the CDR regions. Specifically, mutations in HCDR3 and LCDR3 alter the binding characteristics to reduce off-target effects on red blood cells while maintaining on-target efficacy against CD47-expressing cancer cells
2Reliability
If CD47/SIRPα blockade is used to induce macrophage-mediated phagocytosis, then tumor growth is suppressed, but the mechanism requires precise control to avoid off-target effects on normal cells
Solution Approach 1:
The antibody is engineered with site-specific modifications in the CDR regions that create differential binding affinity. The modified CDR3 regions provide localized changes in binding characteristics that enable selective recognition of CD47 on cancer cells versus CD47 on normal cells, achieving spatially selective action
Solution Approach 2:
The patent uses the modified antibody as an intermediary that facilitates macrophage phagocytosis of cancer cells by blocking the CD47-SIRPα interaction. The engineered antibody acts as a mediator that enhances the natural immune response while being controlled to avoid activating macrophages against normal cells through its selective binding properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IMC-002 demonstrates excellent safety and therapeutic efficacy in patients with advanced or metastatic solid cancers, inducing macrophage-mediated phagocytosis and strongly inhibiting tumor growth, with a favorable safety profile and no significant anemia or hemagglutination.
Implementation Method 1
blockade of CD47/SIRPα interaction has been shown to induce macrophage-mediated phagocytosis of cancer cells
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a method for treating solid cancer using an anti-CD47 antibody.